VivoMedica shareholders approve delisting from AIM

At the General Meeting held in London on April 3rd 2009 shareholders voted in favour of the resolution to cancel admission of the company's ordinary shares to trading on the AIM stock market. As a result, this cancellation will occur from 15 April 2009.

The Board are currently exploring the most cost effective way of providing shareholders with a platform to continue to trade in the Company’s shares and will provide details on the Company’s website in due course.
» Read More

VivoMedica seeks delisting from AIM in the best interests of shareholders

Following careful consideration, the Directors have concluded that it is no longer in the best interests of the Company or its Shareholders to maintain the admission to trading on AIM of the Ordinary Shares and consider that the costs of remaining quoted on AIM far outweigh the benefits.
» Read circular
» Form of Proxy for shareholders

CDI and VivoMedica present first human data

At the recent international conference of the Safety Pharmacology Society held in Madison WI USA, VivoMedica jointly with Cellular Dynamics International (CDI) presented data generated using human cardiomyocytes derived from CDI's human Stem Cells; the data was analysed using VivoMedica's DrugPrint® system. This research shows the potential of this combined system and demonstrates a viable human model for cardiotoxicity screening in drug research.

Scientific Presentations

Effects Of Isoprenaline On Human Stem Cell-Derived Cardiomyocytes » Read Poster presented at SPS conference

An In Vitro Method For Detecting Potential Proarrhythmic Properties Of Cardiomyocytes Grown On Microelectrode Arrays » Read Poster presented at SPS conference

DrugPrint® presented at MEA conference

Following significant progress with the development of VivoMedica's DrugPrint® system, data has been presented to delegates at the recently held 6th International Conference on Substrate-Integrated microelectrode arrays (MEA) in Reutlingen, Germany, where the data was well received. For further details of the data presented and the press release, please clink on the links below.

» Read press release

Scientific Presentation

An In Vitro Method For Detecting Potential Proarrhythmic Properties Of New Chemical Entities: A Novel Analytical Approach For Characterising Cardioactive Drug Effects
» Read Paper presented at MEA conference

DrugPrint® could cut the cost of preclinical research

VivoMedica's DrugPrint® is set to make significant impact on the cost and effectiveness of preclinical cardiotoxicity testing. In a recent article, Tina Tan of the industry publication Clinica interviewed Peter Leyland, CEO of VivoMedica, and discovered how DrugPrint® could reduce drug casualties and reduce the cost of preclinical research in the pharmaceutical industry.

»  Read Clinica Article

VivoMedica and Cellartis to collaborate on DrugPrint®

June 2008 - VivoMedica and Cellartis have recently concluded discussions and signed a non-exclusive agreement to collaborate to develop the application of VivoMedica's DrugPrint® preclinical cardiotoxicity profiling system with Cellartis' stem cell technologies. The need to gain earlier knowledge of the potential cardiotoxic side effects of new drug candidates is an increasingly urgent imperative due to regulatory and commercial pressures. There is also a growing need to reduce animal testing in drug research, and to develop models that are predictive of the likely response in humans. By combining the high value outputs of DrugPrint® with human cardiac cells, the potential of a human ex-vivo model for cardiotoxicity profiling is nearing reality.

»  Read press release

For further information about any of these events please contact us